Last reviewed · How we verify
R-CHOP or R-bendamustine
R-CHOP and R-bendamustine are combination chemotherapy regimens that use rituximab (an anti-CD20 monoclonal antibody) combined with cytotoxic chemotherapy agents to kill B-cell lymphomas.
R-CHOP and R-bendamustine are combination chemotherapy regimens that use rituximab (an anti-CD20 monoclonal antibody) combined with cytotoxic chemotherapy agents to kill B-cell lymphomas. Used for B-cell non-Hodgkin lymphoma (various subtypes), Chronic lymphocytic leukemia.
At a glance
| Generic name | R-CHOP or R-bendamustine |
|---|---|
| Also known as | Rituximab, Cyclophosphamide,, Hydroxydaunorubicin, Oncovin, Prednisone |
| Sponsor | Fondazione Italiana Linfomi - ETS |
| Drug class | Monoclonal antibody + chemotherapy combination |
| Target | CD20 (rituximab component) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Rituximab targets CD20 antigen on B-cell surfaces, triggering antibody-dependent cellular cytotoxicity and direct apoptosis. CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or bendamustine provide additional cytotoxic effects through DNA damage and cell cycle disruption. The combination leverages immunotherapy with conventional chemotherapy for enhanced efficacy in B-cell malignancies.
Approved indications
- B-cell non-Hodgkin lymphoma (various subtypes)
- Chronic lymphocytic leukemia
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Infection
- Nausea/vomiting
- Fatigue
- Infusion reactions (rituximab)
- Mucositis
Key clinical trials
- Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma (PHASE2)
- A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma (PHASE3)
- A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma (PHASE3)
- Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) (PHASE1, PHASE2)
- A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma (PHASE2)
- Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma (PHASE3)
- A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- R-CHOP or R-bendamustine CI brief — competitive landscape report
- R-CHOP or R-bendamustine updates RSS · CI watch RSS
- Fondazione Italiana Linfomi - ETS portfolio CI